Jump to content

Iranian National Formulary

From Wikipedia, the free encyclopedia
A Pharmacy in Iranian city of Nishapur

The Iranian National Formulary (INF) has more than 2,300 molecules registered at the Iran's Ministry of Health, including various strengths and dosage forms. The standards regarding pharmaceutical products in Iran are determined and modified by the Pharmacopeia Council.

Iran has adopted a full generic-based National Drug Policy (NDP), with local production of essential drugs and vaccines as one of the main goals.[1]

Top 20 drug molecules and sales in Iran

[edit]
Top 20 molecules[2][unreliable source]
Molecule Sales for the first 6 month of 2010 (in Iranian Rials)
1 INTERFERON 423,996,630,000
2 CEFIXIME 397,896,015,000
3 AMOXICILLIN 323,624,414,264
4 CO-AMOXICLAV 231,047,948,600
5 ACETAMINOPHEN 210,953,849,492
6 ALBUMIN 210,632,806,000
7 DOCETAXEL 182,924,555,600
8 IMIPENEM+CILASTATAIN 181,099,640,000
9 CLOPIDOGREL 169,915,498,015
10 IMMUNE GLOBULIN 160,575,717,000
11 ENOXAPARIN 145,486,724,600
12 CEFALEXIN 142,499,418,000
13 DEXTROSE 141,272,434,000
14 ATORVASTATIN 132,514,275,600
15 PANTOPRAZOL 130,971,241,400
16 SALMETEROL 127,780,028,000
17 SODIUM CHLORIDE 126,043,613,100
18 IBUPROFEN 125,621,562,500
19 RITUXIMAB 118,690,006,000
20 ERYTHROPOIETIN 110,191,720,000

See also

[edit]

References

[edit]
  1. ^ "Health services and pharmaceuticals to Iran". Austrade. Archived from the original on 6 March 2007.
  2. ^ "Iran Pharma". iran-pharma.blogspot.com. 5 February 2010. Archived from the original on 17 August 2020.